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1. Introduction
Sleep problems are commonplace in patients with schizo-
phrenia (SZ) [1-5], the most prevalent disturbances being 
sleep conciliation and maintenance insomnia [6] which, al-
though rarely the predominant complaint, can often be se-
vere enough to require separate clinical care.
Research reports on polisomnography in SZ patients have 
revealed: difficulty to fall asleep, early awakening and in-
ability to fall asleep again, which reduces the depth of slow-
wave sleep and shortens rapid eye movement (REM) latency 
[1,3,7,8]. Reduced sleep efficiency and total sleep time, in-
creased sleep latency, and alterations of stage 2 sleep, slow 
wave sleep (SWS) and REM sleep variables have been re-
ported in most patients with SZ [5]. This is especially true 
during psychotic episodes [9], but difficulties initiating or 
maintaining sleep are common in the prodromal phase [5,11], 
and recurring episodes. And although sleep architecture may 
improve with antipsychotic treatment, sleep remains mostly 
fragmented and doesn’t recede to its normal pattern [9].
Additionally, studies with actigraphy have revealed that 
there are indeed abnormalities in a substantial number 
of patients, with most showing longer sleep times than 
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Background: Patients with schizophrenia often present sleep complaints which have been related to poor patient quality of life. 
Physiologic sleep, compatible with work routines is necessary, and may translate into better social functioning, engagement in 
rehabilitation strategies, and satisfaction with life. 
Methods: In this cross-sectional, non-interventional study, 811 adult outpatients with a diagnosis of schizophrenia were divided 
into two groups according to the presence (or absence) of sleep disturbances, and assessed using measures of symptom severity, 
quality and patterns of sleep (Pittsburgh Sleep Quality Index - PSQI), personal and social functioning, and satisfaction with life.
Results: Patients with sleep disturbances were significantly more symptomatic, and revealed worse quality of sleep on all com-
ponents of the PSQI (p < 0.0001), as compared to patients without sleep disturbances. Patients with sleep disturbances presented 
significantly worse personal and social functioning and satisfaction with life in all domains. Satisfaction with life of patients 
with sleep disturbances’ caregivers was also significantly worse in all domains.
Personal and social functioning was significantly correlated with sleep quality (r = -0.23328, p < 0.0001), indicating that patients 
with worse quality of sleep have lower levels of functioning in every domain of functioning (p < 0.01). Quality of sleep was also 
significantly correlated with patients’ and caregivers’ satisfaction in all domains (p < 0.01). 
Conclusions: Our findings show that schizophrenia patients reporting sleep disturbances present greater symptom severity 
and worse personal and social functioning. Moreover, both patients with sleep disturbances and their caregivers, report worse 
satisfaction with life.
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controls [11]. Positive and negative symptoms may cor-
relate with important sleep variables such as sleep la-
tency, sleep efficiency, SWS, and REM sleep parameters 
[5,12], although results are contradictory [13]. 
How abnormal sleep develops in SZ patients is still un-
known, and it remains unclear whether sleep problems are 
secondary to social withdrawal and reclusive behavior, to 
medication, or whether they are due to an intrinsic abnor-
mality of the neuroendocrine systems regulating sleep and 
wakefulness [14,15].
Moreover, sleep appears to play an important role in the 
consolidation of memory  [16], and patients with a more 
normal rhythm perform better on cognitive tasks of vi-
suospatial memory, procedural learning, and frontal lobe 
function [13]. This has important implications, and a nor-
mal rest-activity cycle with relative amplitude of day/
night activity may be a prerequisite for adequate cognitive 
functioning in individuals with SZ [13,16]. This, in turn, 
may translate into better social functioning, and/or better 
engagement in rehabilitation strategies.
Poor sleep quality in SZ patients has been related to poor 
patient quality of life [12,17-19]. Nowadays, the aim of 
mental health clinicians is not just to ameliorate symp-
toms, but also to improve functional outcome and satis-
faction with life for SZ patients [20]. To accomplish this, 
physiologic sleep, compatible with work routines and 
timetables is necessary. However, the relationship be-
tween quality of sleep, personal and social functioning, 
and satisfaction with life in SZ outpatients has been un-
derstudied.
The aim of this work was to assess the differences be-
tween symptom severity, functioning level, satisfaction 
with life, and sleep quality perceived by SZ outpatients 
with and without self-reported sleep disturbances. We hy-
pothesized that worse quality of sleep, would be associ-
ated with greater symptom severity, worse personal and 
social functioning and worse satisfaction with life.
2. Material and methods 
Study design
In this multicenter, Iberic, cross-sectional, non-interven-
tional study, outpatients with a diagnosis of SZ aged 18 
years or older were screened for the presence of sleep dis-
turbances1. 
1 In the Spanish version of the study, there was a time-frame of 
1 one week when six patients were included in the “case and 
control” study (three patients reporting sleep disturbances 
and three patients denying sleep disturbances).  In Portugal, 
investigators included 10 patients in the study: 5 with sleep 
disorders and 5 without. In case no patients were recruited 
for the period of 1 week, the investigator was allowed to 
continue recruitment for the following weeks.
Participants
From a total of 1492 screened patients, 811 patients were 
recruited from psychiatric departments November 2010 
to July 2011 (709 in Spain and 102 in Portugal). Patients 
were asked to subjectively report whether they had sleep 
disturbances or not; 401 patients considered themselves 
to have sleep disorders while 410 did not. Inclusion cri-
teria were as follows: outpatients with a diagnosis of SZ 
according to DSM-IV criteria [21], ascertained from in-
terview with their psychiatrist and medical chart review, 
aged 18 years or older, and having been on a stable dose 
of antipsychotic for at least 6 months prior to interview. 
Patients with any type of severe sleep disturbances relat-
ed to disorders other than SZ (e.g. nightmares, nocturnal 
fears, restless leg syndrome) were excluded. Schizoaffec-
tive disorder, organic impairment, or cognitive deficits 
that could influence patients’ self-report were also con-
sidered exclusion criteria. Patients were excluded mainly 
due to unstable antipsychotic treatment, non-consent, lack 
of cognitive ability or other sleep disorders. 
Patients were mainly prescribed atypical antipsychotics: 
risperidone (37%), olanzapine (21%), paliperidone (20%), 
quetiapine (13%), aripiprazol (12%), clozapine (11%), 
haloperidol (9%), amisulpride (6%), levomepromazine 
(5%), zuclopentixol (5%), flufenazine (4%), ziprasidone 
(4%) and others (4%). There were no statistical signifi-
cant differences between patients with sleep disorders as 
compared to patients without sleep disorders regarding 
type of antipsychotic treatment (Table 1); however, pa-
tients with sleep disorders were prescribed significantly 
more anxiolytics and hypnotics (Table 1).
The investigators were aware of the patients’ diagnosis 
and overall clinical status. 
The local Ethics committees approved the study, and all 
participants provided written informed consent. 
Assessment instruments
Symptom severity was evaluated with the Brief Psychiat-
ric Rating Scale (BPRS) [22]. 
The quality and patterns of sleep were measured with 
the Spanish version of the Pittsburgh Sleep Quality In-
dex (PSQI) [23]. This self-report questionnaire rates sleep 
quality and patterns during the previous month, and eval-
uates 7 components of sleep: subjective quality, latency, 
duration, usual efficiency, sleep disturbances, medication 
use, and daytime dysfunction. The score is given through 
a Likert-like scale, between 0 and 3, with a cut-off value 
of 5, higher scores meaning worse sleep quality. 
Social functioning was evaluated with the Portuguese and 
Spanish versions of the Personal and Social Performance 
(PSP) scale [24,25]. The PSP is a brief instrument that as-
sesses four domains of functioning. The ratings are based 
on the assessment of four objective indicators: 1) socially 
useful activities, including work and study; 2) personal 
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and social relationships; 3) self-care; and 4) disturbing 
and aggressive behaviours. These are rated on a six-point 
severity scale (absent to very severe), according to spe-
cific operational definitions. The interviewer assigns a 
global score on a 100-point scale, based upon information 
from interview and other valid sources. Although there 
are no cut-off points, the total score is usually divided into 
three levels: 71-100, reflecting mild or no functioning dif-
ficulties; 31-70, reflecting varying degrees of difficulties; 
and 0-30, reflecting functioning so poor that the patient 
needs intensive support and supervision. 
Patient and caregiver satisfaction with life (job, family, 
sexual, social, health and general satisfaction was evalu-
ated by means of a visual analogue scale.
Statistical analysis
We compared patients reporting sleep disturbances 
versus a control group of patients without sleep distur-
bances. Both groups were compared in their sociode-
mographic, and clinical variables using parametric t-
Student or F-Snedcor. The associations between func-
tioning, sleep and patient and caregiver satisfaction 
were calculated with Pearson’s correlation coefficient. 
The associations between functioning and quality of 
sleep were calculated with Pearson’s correlation. We 
used SAS 9.3. Copyright (c) 2002-2010 by SAS Insti-
tute Inc., Cary, NC, USA.
3. Results
Patients were predominantly male (67%), 84% lived ac-
companied (89% with either their spouse or their parents), 
and the majority was not working (76%). There were no 
statistical differences in gender, age, illness duration, age 
of diagnosis, educational level, and employment status 
between the groups (Table 2).
63% of patients were current smokers, and more pa-
tients with sleep disturbances were smokers (Chi2=9.455, 
p=0.024). The majority of patients (77%) in our study 
denied alcohol consumption; however, more patients 
with alcohol consumption reported sleep disturbances 
(Chi2=7.509, p=0.023).
Patients with sleep disturbances were significantly more 
symptomatic (Table 2), and scored significantly higher 
on all components of the PSQI (p < 0.0001), revealing 
worse quality of sleep, as compared to patients without 
sleep disturbances. Finally, patients with sleep distur-
bances presented significantly worse personal and social 
functioning in every domain of functioning, as well as 
significantly worse satisfaction with life in all domains 
(Table 3). Moreover, the satisfaction with life of patients 
Table 1: Medication prescribed to patients with and without sleep disorders.
___________________________________________________________________________
Treatment until visit day Patients without Patients with sleep All patients
   Sleep disturbances disturbances
   (N = 410) (N = 401) (N= 811) Chi2 p value
___________________________________________________________________________
   N (%) N (%) N (%)
___________________________________________________________________________
Atypical antipsychotics 384 (93.7) 372 (92.8) 756 (93.2) 0.2543 0.6141
Typical antipsychotics 88 (21.5) 88 (22.0) 176 (21.7) 0.0277 0.8678
Antidepressants  101 (24.6) 122 (30.4) 223 (27.5) 3.4087 0.0649
Anxiolytics  133 (32.4) 162 40.4) 295 (36.4) 5.5501 0.0185
Mood stabilizers  34 (8.3) 46 (11.5) 80 (9.9) 2.3037 0.1291
Anticholinergics  55 (13.4) 65 (16.2) 120 (14.8) 1.2560 0.2624
Hypnotics/sedatives 51 (12.4) 107 (26.7) 158 (19.5) 26.2216 <0.0001
 Others 15 (3.7) 26 (6.5) 41 (5.1) 3.3712 0.0663
________________________________________________________________________________________________________________________________________
Table 2: Sociodemographic and clinical characteristics.
________________________________________________________________________________________________________________________
Characteristics Patients without Patients with sleep
  Sleep disturbances disturbances Chi2 p value
  (N = 410) (N = 401) 
_____________________________________________________________________________
_____________________________________________________________________________
  N (%) N (%) N (%)
_____________________________________________________________________________
_____________________________________________________________________________
 Gender (men:women) 270:140 270:131 1.990 0.925
 Educational level
 No education 30 24
 Primary education 166 174 1.939 0.585
 Secondary education 147 148











  mean (SD) mean (SD) t-Student p value
________________________________________________________________________________________________________________________________________
Age 42.7 (11.64) 42.4 (11.72) 0.36 0.716
Age of diagnosis (years) 25.8 (8.67) 25.2 (7.90) 0.90 0.368
Illness duration (years) 16.9 (10.64) 17.2 (11.13) 0.29 0.768
BPRS total score 12.8 (8.27) 16.6 (9.43) 6.05 <0.001
PSQI total score 4.8 (3.30) 11.6 (3.96) 26.72 < 0.001
PSP scale total score 60.6 (16.89) 56.2 (17.60) 3.58 < 0.001
________________________________________________________________________________________________________________________________________
Legend: BPRS: Brief Psychiatric Rating Scale; PSP: Personal and Social Performance; SD: standard 
deviation; PSQI: Pittsburgh Sleep Quality Index
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with sleep disturbances’ caregivers was also significantly 
worse in all domains (Table 4).
For all patients, personal and social functioning was sig-
nificantly negatively correlated with sleep quality (r = 
-0.233, p < 0.0001), indicating that patients with worse 
quality of sleep have lower levels of functioning. This was 
true for every domain of functioning (p < 0.0001). Quality 
of sleep was also significantly correlated with patients’ 
and caregivers’ satisfaction in all domains (p < 0.0001). 
4. Discussion
As hypothesised, patients with worse quality of sleep 
presented greater symptom severity, worse personal 
and social functioning, and less satisfaction with sev-
eral life dimensions. 
To the best of our knowledge, ours is the first study 
showing an association between quality of sleep and 
several domains of personal and social functioning. 
This could be mediated by cognitive function, since 
sleep appears to play an important role in the consoli-
dation of memory [16], and patients with a more nor-
mal rhythm perform better on cognitive tasks of, inde-
pendent of clinical status [13,16]. Therefore, a normal 
rest-activity cycle with relative amplitude of day/night 
activity may be a prerequisite for adequate cognitive 
functioning in individuals with SZ [13,16], which 
could in turn translate into better personal and social 
functioning, and/or better engagement in rehabilitation 
strategies.
Poor sleep quality in SZ patients, has been related to 
poor patient quality of life [612,17-19], even after cor-
recting for depression and drug effects [17-19]. In our 
study, both patients with sleep disturbances and their 
caregivers reported worse satisfaction with life in all 
domains. We are not aware of studies on this associa-
tion, but satisfaction with life may be considered as a 
proxy for quality of life. 
Regarding symptomatology, studies have shown in-
somnia to be associated with increased positive symp-
toms [26], and that these, namely suspiciousness, hal-
lucinations and hyperactivity, are associated with more 
disrupted sleep/wake patterns and circadian activity 
rhythms in SZ patients [12]. It has been purposed that 
positive symptoms could make it harder for the patients 
to fall asleep, due to an increased neurophysiologic 
arousal, explaining the longer sleep latency, and lower 
total sleep time found in this group. On the other hand, 
patients with negative syndrome present low motor ac-
tivity levels [27], possibly facilitating sleep, while im-
proved sleep itself may reduce negative symptoms [28].
Patients with sleep disturbances self-reported worse 
quality of sleep and more daytime sleepiness. Atypical 
antipsychotics tend to improve sleep induction and/or 
sleep maintenance in SZ patients [6], and most atypical 
antipsychotics demonstrate an increase in total sleep 
time and/or sleep efficiency in SZ patients [5]. Clozap-
ine has been shown to increase the total sleep time, sleep 
efficiency, and stage 2 sleep and decrease sleep latency 
and wake time after sleep onset [5,29,30].  Olanzapine 
demonstrates comparable influences on sleep variables 
with an overall improvement in sleep efficiency and an 
increase of REM sleep and SWS [31,32]. A significant 
enhancement of SWS has also been noted in risperi-
done treated patients [33]. Paliperidone has been shown 
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Table 3: Personal and social functioning of patients with and without sleep disorders.
________________________________________________________________________________________________________________________________________
PSP domains Patients without Patients with sleep
  Sleep disturbances disturbances t-Student p value
  (N = 410) (N = 401) 
________________________________________________________________________________________________________________________________________
  mean (SD) mean (SD)
________________________________________________________________________________________________________________________________________
Social activities 3.00 (1.21) 3.28 (1.22) 3.23 0.0013
Personal and social relationships 3.00 (1.15) 3.26 (1.15) 3.22 0.0014
Self-care 1.89 (0.89) 2.17 (1.08) 3.93 < 0.0001
Disturbing and aggressive behavior 1.43 (0.79) 1.65 (0.88) 3.68 0.0003
PSP total score 60.6 (16.89) 56.2 (17.60) 3.58 <0.001
________________________________________________________________________________________________________________________________________
Legend: PSP: Personal and social functioning scale
Table 4: Patients’ and caregivers’ level of satisfaction with life.
________________________________________________________________________________________________________________________________________
PSP domains Patients without Patients with sleep
  Sleep disturbances disturbances t-Student p value
  (N = 410) (N = 401) 
________________________________________________________________________________________________________________________________________
  mean (SD) mean (SD)
________________________________________________________________________________________________________________________________________
Patient satisfaction    
Job satisfaction 4.3 (2.84) 3.4 (2.73) 4.36 < 0.0001
Family satisfaction 6.6 (2.34) 5.8 (2.56) 4.86 < 0.0001
Sexual satisfaction 3.5 (2.83) 3.0 (2.70) 2.57 0.0105
Social life satisfaction 5.4 (2.28) 4.4 (2.35) 5.97 < 0.0001
General satisfaction 6.0 (1.91) 5.0 (2.08) 6.99 < 0.0001
Satisfaction with health 6.5 (1.88) 5.6 (2.11) 6.65 < 0.0001
________________________________________________________________________________________________________________________________________
Caregiver satisfaction (N = 212) (N = 222)  
Job satisfaction 4.1 (2.94) 3.3 (2.57) 4.36 0.0035
Family satisfaction 6.4 (2.33) 5.4 (2.37) 4.86 < 0.0001
Sexual satisfaction 3.9 (2.72) 3.1 (2.65) 2.57 0.0013
Social life satisfaction 4.8 (2.10) 3.8 (2.18) 5.97 < 0.0001
General satisfaction 5.8 (1.88) 4.7 (1.91) 6.99 < 0.0001
Satisfaction with health 6.5 (1.82) 5.5 (2.07) 6.65 < 0.0001
________________________________________________________________________________________________________________________________________
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to reduce persistent sleep latency, sleep onset latency, 
number of awakenings after sleep onset, time awake in 
bed, stage 1 sleep duration, and to cause a prolongation 
in total sleep time, sleep period time, stage 2 and REM 
sleep duration, and an increase in the sleep efficiency 
index measured by polisomnography [34]. Concerning 
quetiapine, ziprasidone, and aripiprazole we are not 
aware of studies with these antipsychotics on the qual-
ity of sleep of SZ patients. Despite that, quetiapine and 
ziprasidone improve sleep induction and consolidation 
in healthy individuals [35,36]. Information on the ef-
fect of long-acting injectable antipsychotics on sleep is 
also sparse, although paliperidone palmitate in acutely 
exacerbated SZ patients has been shown to improve 
sleep quality compared with placebo [37].
Antipsychotic treatment can produce akathisia, which 
is characterized by intense motor restlessness and pac-
ing, and restless legs syndrome (RLS) [5]. The preva-
lence of RLS in antipsychotic-treated schizophrenic 
patients has been reported to be more than twice that 
of healthy controls [38].  Clinicians should be aware 
for these side effects, since they can cause significant 
sleep disruption. 
Daytime somnolence is a relatively common side ef-
fect of antipsychotic treatment, ranged from 24% to 
31% in SZ patients [39] and may contribute to non-
compliance and potentially to a poorer outcome. Som-
nolence in antipsychotic-treated schizophrenic pa-
tients can lead to daytime naps. Consequently, these 
patients can develop sleep reversals and polyphasic 
sleep patterns with a negative impact on nighttime 
sleep. Sleep hygiene and other behavioral treatments 
are widely available and may have beneficial effects 
on these patients.
However, to disentangle the effects of SZ itself from 
the influence of medication on sleep is difficult [5], 
and although we did not stratify the patients by type 
and/or dose of medication, it seems unlikely that treat-
ment alone could explain the differences between 
the groups. Previous studies have shown that these 
variable sleep patterns are also unlikely to be simply 
caused by having unstructured days without any rou-
tine, since when compared to unemployed individuals 
who may also not have a pattern to their daily lives, the 
differences persist [11]. Interestingly, an association 
between having a daily occupation, and better sleep 
quality and lower sleep latency has been previously 
reported [12], indicating that social and professional 
rehabilitation could reflect positively in the patients’ 
circadian rhythms.
Our study has several limitations: the lack of objective 
evaluation of sleep (i.e. polisomnography or actigra-
phy) allowed only for the study of patients’ percep-
tions. We included patients who were taking benzodi-
azepines and other psychotropics and did not control 
for the effect of type and dose of antipsychotic and/or 
other medicines. Stimulant use (e.g. coffee, tea, etc) 
and alcohol use was also not controlled for. Although 
sleep apnea was an exclusion criterion, we cannot 
guarantee that some of our sample may have undi-
agnosed sleep apnea, which may contribute to sleep 
difficulties. Severe insomnia has been associated with 
significantly higher body mass indexes [19], which 
we did not control for. Our patients presented elevated 
symptom levels, and therefore our results may not be 
applicable to patients in remission. Finally, our results 
from an Iberic population may not apply to other coun-
tries/cultures, and therefore need further replication.
Strengths of the study include the sample size and its 
naturalistic nature, representing “real-life” patients.
5. Conclusions
Our results show that patients reporting sleep distur-
bances show greater symptom severity, and worse per-
sonal and social functioning. Moreover, both patients 
with sleep disturbances and their caregivers self-report 
worse satisfaction with life. These disturbances may 
reinforce altered sleep patterns, cognitive deficits and 
social engagement associated with SZ, with a negative 
impact on rehabilitation strategies. 
Although not a diagnostic criterion, sleep disturbance 
is prevalent in SZ patients, and the identification of 
sleep complaints is of the utmost importance. Careful 
history taking, and the use of sleep diaries, will usually 
lead to a proper characterization of sleep disturbances 
with practical therapeutic implications. Given the suc-
cess in improving sleep through behavioral interven-
tions such as sleep hygiene, particularly enforcement 
of stable sleep and wake times, in various populations 
[40] it might benefit patients with SZ as well. Improve-
ment in cognition, functioning, as well as satisfaction 
with life of people with SZ may also depend on im-
proving sleep parameters. Nevertheless, this important 
area has received lack of attention from SZ researchers, 
despite the positive impact that treatments should have 
on these variables. 
Conflicts of Interest
The authors report no conflict of interest. 
Sofia Brissos and Ivan Bernardo-Fernandez at the time 
of this study (2011) were full-time employees of Jans-
sen Pharmaceutical in Portugal and Spain respectively, 
as Medical Affairs Managers.
Funding and Support
This study was supported by Janssen. The sponsor of 
the study had no role in the collection and analysis of 
the data, or preparation of the manuscript.
38
Acknowledgements
The authors thank the following study investigators: 
Portugal: António Bajouco, Gisela Borges, Pedro Car-
valho, Elsa Lara, Luciano Marmelada, Fernanda Rosa; 
Spain: Alberto Fuentes, Alexandre Pons i Villanueva, 
Alfonso Rodríguez, Alfredo Cortell, Alfredo Galindo, 
Ana Isabel González, Andrés González, Andrés Mar-
tín, Andrés Porcel, Ángel Royuela, Antonio Agüera, 
Antonio Carrillo, Antonio Galbis, Antonio Martínez, 
Blanca Fernández-Abascal, Carlos José Pino, Carlos 
Riaza, Carmen Moreno, Carmen Pernía, César Antón, 
Clara Pedrejón, Consuelo de Dios, Cristina García, 
Desiderio Mejías, Luis Goenechea, Ignacio Zarranz, 
Patricia Llorens, Elena de las Heras, Elisabet Gorgues 
i Queralt, Eloísa Gloria Román, Enrique Daniel Vega, 
Esther García, Eva Fontela, Evaristo Nieto, Francisco 
Arnau Feiró, Francisco de Vicente, Francisco del Río, 
Francisco Gázquez, Francisco Javier Fernández, Guil-
lermo Lahera, Guillermo Masana, Horacio Watman, 
Jaqueline Mayoral, Javier Alberca, Jesús Enrique Me-
sones, Jesús Salomón, Joan Cadevall, Jorge Domingo 
Ribas, José Antonio Juan, José Carlos Rodríguez, José 
Carmona, José Luis Gálvez, José Manuel Crespo, José 
Manuel Perea, José María Martínez, José Salazar, Juan 
Carlos García, Juan Carlos Giménez, Juan Carlos Gó-
mez, Juan Carlos López, Juan Carlos Ortigosa, Juan 
José Fernández, Juan José Gea, Juan Pablo Vedia, Julia 
Fraga, Julia García-Albea, Ladislao García, Leonardo 
Moyano, Luis Ignacio Rodríguez, Luis Mínguez, Luis 
Santa-María, Lydia Gayubo, Maria Carmen García 
Mahía, Maria Eulalia Jaén, Maria Lourdes Fernández, 
Maria Rosario Cejas, Manuel Soria, María Aránzazu 
Sánchez, María Elena Caruezo, María José Márquez, 
María Peñitas Ríos, Mercé Aubareda, Mercedes Guz-
mán, Micaela González-Quirós, Miguel Alfonso Gar-
cía, Miguel Hernández, Miguel Lliteras, Miguel Soler, 
Olga Sobrino, Pablo Álvarez, Pedro A. Sopelana, Pe-
dro Ecénarro, Pedro Vicente Canut, Rafael Fernández 
Gª-Andrade, Ramón Planet, Raquel Largo, Raúl Váz-
quez-Noguerol, Rosa Catalán, Rosa González, Rosa 
Villanueva, Salustiano Campos, Salvador Martínez, 
Salvador Ros, Santiago Navarro, Santiago Sánchez, 
Sara González, Sara Sole, Saulo Pérez Gil, Susana Ál-
varez, Valero Pérez, Vicente Berenguer, Vicente Tor-
dera, Victoria Caramés, Virgilio Traid, xavier Fluvià.
References
1.  Keshavan MS, Reynolds CF 3rd, Miewald MJ, Mon-
trose DM, Sweeney JA, Vasko RC Jr, Kupfer DJ. 
Delta sleep deficits in schizophrenia: evidence from 
automated analyses of sleep data. Arch Gen Psychia-
try 1998; 55(5):443-8.
2.  Taylor SF, Tandon R, Shipley JE, Eiser AS. Ef-
fect of neuroleptic treatment on polysomnographic 
measures in schizophrenia. Biol Psychiatry 1991; 
30:904-912.
3.  Tandon R, Shipley JE, Taylor S, Greden JF, Eiser 
A, DeQuardo J, Goodson J. Electroencephalographic 
sleep abnormalities in schizophrenia: Relationship 
to positive/negative symptoms and prior neuroleptic 
treatment. Arch Gen Psychiatry 1992, 49:185-194.
4.  Monti JM, Monti D. Sleep disturbance in schizo-
phrenia. Int Rev Psychiatry 2005, 17(4):247-53.
5.  Cohrs S. Sleep disturbances in patients with schizo-
phrenia: Impact and effect of antipsychotics. CNS 
Drugs 2008, 22:939-962. 
6.  Monti JM, Monti D. Sleep in schizophrenia patients 
and the effects of antipsychotic drugs. Sleep Med 
Rev 2004, 8:133-148. 
7.  Wetter TC, Lauer CJ, Gillich G, Pollmächer T. The 
electroencephalographic sleep pattern in schizo-
phrenic patients treated with clozapine or clas-
sical antipsychotic drugs. J Psychiatr Res 1996, 
30(6):411-419.
8.  Wirz-Justice A, Haug HJ, Cajochen C. Disturbed 
circadian rest-activity cycles in schizophrenic pa-
tients: An effect of drugs? Schizophrenia Bull 2001, 
27:497-502.
9.  Kupfer DJ, Wyatt RJ, Scott J, Syder F. Sleep distur-
bance in acute schizophrenic patients. Am J Psychia-
try 1970, 126:1213-1223.
10.  Donlon PT, Blacker KH. Clinical recognition of 
early schizophrenic decompensation. Dis Nerv Syst 
1975, 36(6):323-327.
11.  Wulff K, Dijk DJ, Middleton B, Foster RG, Joyce 
EM. Sleep and circadian rhythm disruption in schi-
zophrenia. Br J Psychiatry 2012, 200(4):308-316.
12.  Afonso P, Brissos S, Figueira ML, Paiva T. Schi-
zophrenia patients with predominantly positi-
ve symptoms have more disturbed sleep-wake 
cycles measured by actigraphy. Psychiatry Res 
2011,189(1):62-6. 
13.  Bromundt V, Köster M, Georgiev-Kill A, Opwis K, 
Wirz-Justice A, Stoppe G, Cajochen C. Sleep-wake 
cycles and cognitive functioning in schizophrenia. 
Br J Psychiatry 2011, 8(4):269-76. 
14.  Wulff K, Joyce E, Middleton B, Dijk DJ, Foster 
RG. The suitability of actigraphy, diary data, and 
urinary melatonin profiles for quantitative assess-
ment of sleep disturbances in schizophrenia: a case 
report. Chronobiol Int 2006, 23(1-2):485-495.
15.  Afonso P, Figueira ML, Paiva T. Sleep-promoting 
action of the endogenous melatonin in schizophre-
nia compared to healthy controls. Int J Psychiatry 
Clin Pract 2011,  15(4):311-315.
16.  Wulff K, Joyce E. Circadian rhythms and cognition 




17.  Ritsner M, Kurs R, Ponizovsky A, Hadjez J. Per-
ceived quality of life in schizophrenia: relationships 
to sleep quality. Qual Life Res 2004, 13(4):783-791.
18.  Hofstetter JR, Lysaker PH, Mayeda AR. Quality of 
sleep in patients with schizophrenia is associated 
with quality of life and coping. BMC Psychiatry 
2005, 5:13.
19.  Palmese LB, DeGeorge PC, Ratliff JC, Srihari VH, 
Wexler BE, Krystal AD, Tek C. Insomnia is fre-
quent in schizophrenia and associated with night 
eating and obesity. Schizophr Res 2011, 133(1-
3):238-243.
20.  Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gat-
taz WF, Möller HJ. WFSBP Task Force on Treat-
ment Guidelines for Schizophrenia. World Federa-
tion of Societies of Biological Psychiatry (WFSBP) 
guidelines for biological treatment of schizophre-
nia, part 2: long-term treatment of schizophrenia. 
World J Biol Psychiatry 2006, 7(1):5-40.
21.  American Psychiatric Association. Diagnostic and 
Statistical Manual of Mental Disorders. Washing-
ton, DC, 4th ed. (DSM IV-TR), 2000. 
22.  Overall JE, Gorham DR. The Brief Psychiatric Ra-
ting Scale (BPRS). recent developments in ascer-
tainment and scaling. Psychopharmacol Bull 1988, 
24:97-99
23.  Buisse DJ, Reynolds CF, Monk TH, Berman SR, 
Kupfer DJ. The Pittsburgh Sleep Quality Index: 
A new instrument for psychiatric practice and re-
search. Psychiatry Res 1989, 28:193-213.
24.  Brissos S, Palhavã F, Marques JG, Mexia S, Carmo 
AL, Carvalho M, Dias C, Franco JD, Mendes R, 
Zuzarte P, Carita AI, Molodynski A, Figueira ML. 
The Portuguese version of the Personal and Social 
Performance Scale (PSP): reliability, validity, and 
relationship with cognitive measures in hospita-
lized and community schizophrenia patients. Soc 
Psychiatry Psychiatr Epidemiol 2011 Jul 8. [Epub 
ahead of print]
25.  Garcia-Portilla MP, Saiz PA, Bousoño M, Bascaran 
MT, Guzmán-Quilo C, Bobes J.Validation of the 
Spanish Personal and Social Performance scale 
(PSP) in outpatients with stable and unstable schi-
zophrenia. Rev Psiquiatr Salud Ment 2011, 4:9-18
26.  Poulin J, Daoust AM, Forest G, Stip E, Godbout R. 
Sleep architecture and its clinical correlates in first 
episode and neuroleptic-naive patients with schizo-
phrenia. Schizophr Res 2003, 62(1-2):147-153.
27.  Walther S, Koschorke P, Horn H, Strik W. Objec-
tively measured motor activity in schizophrenia 
challenges the validity of expert ratings. Psychiatry 
Res 2009, 169(3):187-190. 
28.  Kato M, Kajimura N, Okuma T, Sekimoto M, Wa-
tanabe T, Yamadera H, Takahashi K. Association 
between delta waves during sleep and negative 
symptoms in schizophrenia. Pharmaco-eeg stud-
ies by using structurally different hypnotics. Neu-
ropsychobiology 1999, 39(3):165-172.
29.  Hinze-Selch D, Mullington J, Orth A, Lauer CJ, 
Pollmächer T. Effects of clozapine on sleep: a lon-
gitudinal study. Biol Psychiatry  1997, 42:260-266.
30.  Lee JH, Woo JI, Meltzer HY: Effects of clozapine 
on sleep measures and sleep-associated changes 
in growth hormone and cortisol in patients with 
schizophrenia. Psychiatry Res  2001, 103:157-166.
31.  Salin-Pascual RJ, Herrera-Estrella M, Galicia-Po-
lo L, Laurrabaquio MR. Olanzapine acute admin-
istration in schizophrenic patients increases delta 
sleep and sleep efficiency. Biol Psychiatry 1999, 
46:141-143.
32.  Müller MJ, Rossbach W, Mann K, Röschke J, Mül-
ler-Siecheneder F, Blümler M, Wetzel H, Russ H, 
Dittmann RW, Benkert O. Sub chronic effects of 
olanzapine on sleep EEG in schizophrenic patients 
with predominantly negative symptoms. Pharma-
copsychiatry 2004, 37(4):157-162.
33.  Yamashita H, Morinobu S, Yamawaki S, Horigu-
chi J, Nagao M: Effect of risperidone on sleep in 
schizophrenia: a comparison with haloperidol. Psy-
chiatry Res 2002, 109(2).137–142. 
34.  Luthringer R, Staner L, Noel N, Muzet M, 
Gassmann-Mayer C, Talluri K, Cleton A, Eerdek-
ens M, Battisti WP, Palumbo JM. A double-blind, 
placebo-controlled, randomized study evaluating 
the effect of paliperidone extended-release tablets 
on sleep architecture in patients with schizophre-
nia. Int Clin Psychopharmacol 2007, 22(5):299-
308.
35.  Cohrs S, Meier A, Neumann A-C, Jordan W, Rüther 
E, Rodenbeck A. Improved sleep continuity and in-
creased slow wave sleep and REM latency during 
ziprasidone treatment: a randomized, controlled, 
crossover trial of 12 healthy male subjects. J Clin 
Psychiatry 2005, 66(8):989-996.
36.  Cohrs S, Rodenbeck A, Guan Z, Pohlmann K, Jor-
dan W, Meier A, Rüther E. Sleep-promoting prop-
erties of quetiapine in healthy subjects. Psycho-
pharmacology 2004, 174(3):421-429.
37.  Pandina GJ, Lindenmayer JP, Lull J, Lim P, Gopal 
S, Herben V, Kusumakar V, Yuen E, Palumbo J. A 
randomized, placebo-controlled study to assess the 
efficacy and safety of 3 doses of paliperidone pal-
mitate in adults with acutely exacerbated schizo-
phrenia. J Clin Psychopharmacol 2010, 30(3):235-
244.
38.  Kang SG, Lee HJ, Jung SW, Cho SN, Han C, Kim 
YK, Kim SH, Lee MS, Joe SH, Jung IK, Kim L. 
Characteristics and clinical correlates of restless 
Personal and social functioning and satisfaction with life in schizophrenia outpatients with and without sleep disturbances
40
legs syndrome in schizophrenia. Prog Neuropsy-
chopharmacol Biol Psychiatry 2007, 31(5):1078-
1083. 
39.  Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, 
Rosenheck RA, Perkins DO, Keefe RS, Davis SM, 
Davis CE, Lebowitz BD, Severe J, Hsiao JK. Cli-
nical Antipsychotic Trials of Intervention Effec-
tiveness (CATIE) Investigators. Effectiveness of 
antipsychotic drugs in patients with chronic schi-
zophrenia. N Engl J Med 2005, 353(12):1209-1223.
40.  Morin CM, Bootzin RR, Buysse DJ, Edinger JD, 
Espie CA, Lichstein KL. Psychological and beha-
vioral treatment of insomnia: update of the recent 
evidence (1998-2004). Sleep 2006, 29(11):1398-
414.
Pedro Afonso
